Total Health Care Spending Projected Grow 70% by 2021
Research Driven Investing Provides Stocks Research on Mylan and Teva Pharmaceutical
NEW YORK, NY -- (Marketwire) -- 02/08/13 -- Health Care stocks have been on an impressive run to start 2013. The Affordable Care Act will provide millions of Americans with access to healthcare, creating new revenue streams for companies across the sector. Research Driven Investing examines investing opportunities in the Health Care Sector and provides equity research on Mylan Inc. (NASDAQ: MYL) and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA).
The Affordable Care Act (Obamacare) requires every American to acquire health insurance by 2014 or be subjected to a tax. For those who can't afford health insurance they will be offered subsidies or Medicaid. Statistics from the Census Bureau show that approximately 50 million Americans did not have health insurance in 2009.
According to the Centers for Medicare and Medicaid Services total health care spending is projected to grow from an estimated $2.8 trillion last year to $4.8 trillion by 2021, an increase of 70 percent. "There's just a lot more money flowing into health care and we're seeing the markets react accordingly," says Invesco portfolio manager, Derek Taner.
Research Driven Investing releases regular market updates on the Health Care Sector so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and industry newsletters.
Mylan offers a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, they offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. Mylan is scheduled to release results for the fourth quarter on Monday February 18th.
Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in about 60 countries. The company reported revenues in the U.S. declined 14 percent year-over-year to $2.6 billion (50 percent of total revenues) in the fourth quarter. The drop in revenues was largely attributable to slowing sales of Provigil which received generic competition in the second quarter of 2012.
Research Driven Investing has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: